This is done at a hospital or clinic as an outpatient procedure. It's covered in angina patients but the angina has to be class III or class IV (in Canada). In the US, it's covered for patients with any class of angina. http://globalcardiocare.com/history_of_eecp
Here's what I found interesting:
Progenitor cells were measured before and each week for four weeks during therapy and progenitor cells increased each week. “One possible explanation for the long-term benefit is that EECP is a regenerative therapy. Progenitor cells line the endothelium. The shear forces described above are forceful enough to dislodge these cells so they enter the circulation. These cells will find damaged endothelium, ischemic myocardium or apoptotic cells and will proliferate so the benefit extends well beyond the treatment period. The number of circulating stem cells has been correlated with vascular disease, age and prognosis. Thus increasing these circulating cells seems a reasonable target for therapy “ http://doc2doc.bmj.com/forums/medical-e ... ve-therapy
The mechanism of increased shear is reversal of flow at the endothelial border
Endothelial stem cells break free into the bloodstream and then head off to find damaged endothelium elsewhere in the body to heal?
It's from this article: January 1, 2010, "EECP is a Regenerative Therapy," published in Frontiers in Bioscience magazine, clinical researchers from Texas A&M Health Science Center College of Medicine and Cardiology
Health is a state when regeneration is in balance with degeneration. Disease can occur if either regeneration or degeneration is out of balance.